Aridis Pharmaceuticals is buying Kenta Biotech’s anti-infection treatment products for an undisclosed amount.
The acquisition includes six products to treat infections, such as skin infections or respiratory infections, caused by common pathogens. Aridis is also buying a technology that helps discover naturally occurring protective antibodies generated by the human immune system. Terms of the deal were not disclosed.
Aridis, headquartered in San Jose, Calif., focuses on developing anti-infective drugs to treat lung infections and other infections.
Zurich-based Kenta also develops medications to treat infections.
Other recent pharmaceutical deals include Takeda Pharmaceutical Co. Ltd.’s purchase of Inviragen, Auxilium Pharmaceuticals Inc.’s (Nasdaq: AUXL) Actient Holdings LLC and Opko Health Inc.’s (NYSE: OPK) acquisition of Prolor Biotech Inc. (NYSE: PBTH).